Status:
COMPLETED
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Esophageal Cancer
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemothe...
Eligibility Criteria
Inclusion
- Advanced, recurrent or metastatic gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus
- EGFR positive tumor
- KPS greater than 60
- Normal cardiac function
- Adequate liver and bone marrow function
- GFR greater than 60 ml/minute
Exclusion
- Previous chemotherapy
- Uncontrolled angina pectoris, heart failure, clinically significant uncontrolled cardiac arrythmias
- Clinically significant ECG or cardiac history
- Radiotherapy or surgery within last 4 weeks
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00113581
Start Date
October 1 2002
End Date
January 1 2007
Last Update
February 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden Hospital
London, United Kingdom